



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)




## Product Information

|                              |  |
|------------------------------|--|
| <b>Description:</b>          | This anti-EGFR antibody is a purified, humanized recombinant monoclonal antibody that recognizes the extracellular domain of human EGFR (epidermal growth factor receptor). The heavy chain contains a C-terminal Avi-Tag™. This antibody has been tested for binding activity by ELISA.   |
| <b>Background:</b>           | EGFR (epidermal growth factor receptor) is the receptor for members of the EGF family and is a transmembrane glycoprotein that has tyrosine kinase activity. Binding of epidermal growth factor to EGFR induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation, differentiation, motility, and cell survival. Activation of EGFR triggers mitogenic signaling in gastrointestinal mucosa, and its expression is upregulated in colon cancers and most neoplasms. EGFR activates the ERK (extracellular signal-regulated kinase)-signaling pathway in normal gastric epithelial and colon cancer cell lines. Inactivation of EGFR with selective inhibitors significantly reduces ERK2 activation, c-fos mRNA expression and cell proliferation, opening new therapeutic opportunities. |
| <b>Species:</b>              | Human  |
| <b>Isotype:</b>              | IgG1   |
| <b>Clonality:</b>            | Monoclonal   |
| <b>Concentration:</b>        | 1.46 mg/ml   |
| <b>Expression System:</b>    | HEK293   |
| <b>Purity:</b>               | ≥90%   |
| <b>Format:</b>               | Aqueous buffer solution.   |
| <b>Formulated In:</b>        | 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol  |
| <b>MW:</b>                   | Heavy chain: 51 kDa + glycans; Light chain: 23 kDa   |
| <b>Glycosylation:</b>        | This antibody runs at a higher MW by SDS-PAGE due to glycosylation.  |
| <b>Stability:</b>            | At least 6 months at -80°C.  |
| <b>Storage:</b>              | -80°C  |
| <b>Instructions for Use:</b> | Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.   |
| <b>Assay Conditions:</b>     | A white 96-well plate was precoated with EGFR, His-Avi-Tag, Biotin-Labeled Recombinant (#102676) (100 ng/well). Blocking Buffer 3 (#79743) and PBST were used for blocking and washing steps, respectively. For protein titration a serial dilution of Anti-EGFR, Avi-Tag Antibody (#102551) at the highest concentration of 2 ng/μl (100 ng/reaction) was prepared in 1x PP-02 Assay Buffer. Diluted anti-EGFR was then added to the wells and incubated at Room Temperature (RT) for 1 hour. The plate was then washed again and incubated with Anti-Fc-HRP diluted 1:1000 in Blocking Buffer 3 for 1 hour at RT. After the final wash, ELISA ECL substrate mix (#79670) was added to each well and chemiluminescence was read.  |
| <b>Applications:</b>         | Useful for binding assays.   |

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



Binding Activity of Anti-EGFR to EGFR

